^
    Back
    Association details:
    Biomarker:TACC2-FGFR2 fusion
    Cancer:Gastric Cancer
    Drug Class:FGFR21 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2022
    Title:

    6199 - Fusion genes: Novel therapeutic targets for gastric signet ring cell carcinoma

    Published date:
    03/09/2022
    Excerpt:
    Also, TACC2-FGFR2-expressing GC cells were more sensitive to FGFR2 inhibitors.